ASA MAIR: Open Payments
NPI 1306458062 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,369 in 156 payments from 18 companies in 2025. Trend: 2023 $550 · 2024 $2,077 · 2025 $2,369
Food & beverage: $2,259Education: $109
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 21 | $273 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $272 |
| Alkermes, Inc. | 19 | $258 |
| ABBVIE INC. | 19 | $246 |
| Teva Pharmaceuticals USA, Inc. | 9 | $240 |
| Otsuka America Pharmaceutical, Inc. | 16 | $192 |
| Vanda Pharmaceuticals Inc. | 13 | $166 |
| E.R. Squibb & Sons, L.L.C. | 14 | $162 |
| Axsome Therapeutics, Inc. | 9 | $150 |
| Neurocrine BioSciences, Inc. | 3 | $96 |
Products named: Qelbree, CAPLYTA, ARISTADA, REXULTI, VRAYLAR, FANAPT, COBENFY, Auvelity.
Industry payments across CA — which companies pay providers there.
